Articles on Avandamet (rosiglitazone with metformin) from NPS RADARArticles on Avandamet (rosiglitazone with metformin) from NPS RADAR

Title Content Type Date Description
Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus Professional publication - NPS RADAR - Review 2008-12-01 00:00:00 Rosiglitazone improves glycaemic control but there is a lack of evidence that it improves diabetes–related clinical complications and mortality. Rosiglitazone is no longer indicated in combination with insulin or for triple oral therapy in combination with metformin and a sulfonylurea. Rosiglitazone is a third-line choice. It may still be considered as part of dual therapy when either metformin or a sulfonylurea is contraindicated or not tolerated. Insulin should also be considered instead of rosiglitazone in these scenarios. Do not use rosiglitazone in people with heart failure or a history of heart failure.
Rosiglitazone with metformin combination tablets (Avandamet) listed on the PBS. Professional publication - NPS RADAR - Brief item 2006-12-01 00:00:00 Rosiglitazone with metformin in a fixed-dose combination tablet (Avandamet) was listed on the PBS as a third-line choice, after metformin and/or a sulfonylurea.

NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.

Date published: 2009-10-30 00:00:00

Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.

References to brands should not be taken as an endorsement by NPS.